The manufacturers of exenatide, liraglutide, lixisenatide, dulaglutide, and semaglutide are among the top 50 pharmaceutical companies in terms of global sales and are ranked 9th, 15th, 8th, 13th, and 15th, respectively (2022 rankings)
10.1016/j.bbamcr.2022.119300 Biochim
Summary Integrating GLP-1 RA therapy with tailored resistance exercise and caloric restriction with dietary counseling, including adequate protein intake (1.21.6 g/kg/day), may help preserve muscle mass and function in older adults
Tightening of pricing and market access, an increase in competitive intensity, unexpected safety signals, or manufacturing supply constraints within the GLP-1/GIP space could have a significant impact on their overall R&D returns
A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy
adult obesity rate declined to 37%, down from a record high of 39.9% in 2022